Kenvue Inc. (NYSE:KVUE) Shares Bought by Alberta Investment Management Corp

Alberta Investment Management Corp increased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 23.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 582,895 shares of the company's stock after buying an additional 109,700 shares during the period. Alberta Investment Management Corp's holdings in Kenvue were worth $12,445,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in KVUE. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue during the fourth quarter worth $29,000. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the third quarter valued at about $35,000. Finally, Versant Capital Management Inc increased its stake in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 3.9 %

Shares of NYSE KVUE traded up $0.88 during trading on Friday, hitting $23.27. 16,393,276 shares of the company were exchanged, compared to its average volume of 13,506,300. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a fifty day moving average price of $21.29 and a 200-day moving average price of $22.14. The firm has a market capitalization of $44.61 billion, a PE ratio of 43.88, a P/E/G ratio of 2.61 and a beta of 1.45.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of several research analyst reports. Canaccord Genuity Group lowered their price objective on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Piper Sandler upgraded Kenvue from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Barclays decreased their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a report on Friday, January 17th. Finally, Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.